Hello, everyone, and how are you this morning? We are doing just fine, thank you, despite the gray skies hovering over the exceedingly quiet and nearly balmy Pharmalot campus. Although it appears snowflakes should be falling, given the time of year, it is actually quite mild in these parts. Nonetheless, we are savoring another hot cup of stimulation to help the neurons do their thing. Please feel free to join us. Meanwhile, here are a few items of interest. Hope your day goes well, of course, and please do stay in touch.

Moderna (MRNA) shipped the first batch of its coronavirus vaccine to U.S. government researchers, who will launch the first human tests of whether the shot could help suppress the epidemic originating in China, The Wall Street Journal reports. The National Institute of Allergy and Infectious Diseases expects to start a clinical trial of about 20 to 25 healthy volunteers by the end of April, testing whether two doses of the shot are safe and induce an immune response likely to protect against infection. Initial results could become available in July or August.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy